The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Intravenous Injection General Anesthesia Drugs Market Research Report 2025
Synopsis
Intravenous general anesthesia refers to a method in which one or several drugs are injected intravenously and act on the central nervous system through blood circulation to produce general anesthesia. According to different administration methods, intravenous anesthesia can be divided into single administration method, divided administration method and continuous administration method. Due to some limitations of its own, the use of intravenous general anesthesia was once limited. However, since the 1980s, with the continuous improvement of clinical pharmacology research methods, the development of new strong and short-acting intravenous anesthetics and the advent of computerized intravenous automatic drug delivery systems, intravenous anesthesia has been greatly improved. And development, has now become the mainstream general anesthesia solution.
Global Intravenous Injection General Anesthesia Drugs market is projected to reach US$ 2444.1 million in 2029, increasing from US$ 1584 million in 2022, with the CAGR of 6.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Intravenous Injection General Anesthesia Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Intravenous Injection General Anesthesia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Maruishi
Lunan Pharmaceutical Group Corporation
Segment by Type
Propofol
Sevoflurane
Remifentanil
Etomidate
Isoflurane
Other
Segment by Application
Hopitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Intravenous Injection General Anesthesia Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Intravenous general anesthesia refers to a method in which one or several drugs are injected intravenously and act on the central nervous system through blood circulation to produce general anesthesia. According to different administration methods, intravenous anesthesia can be divided into single administration method, divided administration method and continuous administration method. Due to some limitations of its own, the use of intravenous general anesthesia was once limited. However, since the 1980s, with the continuous improvement of clinical pharmacology research methods, the development of new strong and short-acting intravenous anesthetics and the advent of computerized intravenous automatic drug delivery systems, intravenous anesthesia has been greatly improved. And development, has now become the mainstream general anesthesia solution.
Global Intravenous Injection General Anesthesia Drugs market is projected to reach US$ 2444.1 million in 2029, increasing from US$ 1584 million in 2022, with the CAGR of 6.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Intravenous Injection General Anesthesia Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Intravenous Injection General Anesthesia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Maruishi
Lunan Pharmaceutical Group Corporation
Segment by Type
Propofol
Sevoflurane
Remifentanil
Etomidate
Isoflurane
Other
Segment by Application
Hopitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Intravenous Injection General Anesthesia Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Intravenous Injection General Anesthesia Drugs Market Overview
1.1 Product Overview and Scope of Intravenous Injection General Anesthesia Drugs
1.2 Intravenous Injection General Anesthesia Drugs Segment by Type
1.2.1 Global Intravenous Injection General Anesthesia Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Propofol
1.2.3 Sevoflurane
1.2.4 Remifentanil
1.2.5 Etomidate
1.2.6 Isoflurane
1.2.7 Other
1.3 Intravenous Injection General Anesthesia Drugs Segment by Application
1.3.1 Global Intravenous Injection General Anesthesia Drugs Market Value by Application: (2023-2029)
1.3.2 Hopitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Intravenous Injection General Anesthesia Drugs Market Size Estimates and Forecasts
1.4.1 Global Intravenous Injection General Anesthesia Drugs Revenue 2018-2029
1.4.2 Global Intravenous Injection General Anesthesia Drugs Sales 2018-2029
1.4.3 Global Intravenous Injection General Anesthesia Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Intravenous Injection General Anesthesia Drugs Market Competition by Manufacturers
2.1 Global Intravenous Injection General Anesthesia Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Intravenous Injection General Anesthesia Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Intravenous Injection General Anesthesia Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Intravenous Injection General Anesthesia Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Intravenous Injection General Anesthesia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Intravenous Injection General Anesthesia Drugs, Product Type & Application
2.7 Intravenous Injection General Anesthesia Drugs Market Competitive Situation and Trends
2.7.1 Intravenous Injection General Anesthesia Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Intravenous Injection General Anesthesia Drugs Players Market Share by Revenue
2.7.3 Global Intravenous Injection General Anesthesia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Intravenous Injection General Anesthesia Drugs Retrospective Market Scenario by Region
3.1 Global Intravenous Injection General Anesthesia Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Intravenous Injection General Anesthesia Drugs Global Intravenous Injection General Anesthesia Drugs Sales by Region: 2018-2029
3.2.1 Global Intravenous Injection General Anesthesia Drugs Sales by Region: 2018-2023
3.2.2 Global Intravenous Injection General Anesthesia Drugs Sales by Region: 2024-2029
3.3 Global Intravenous Injection General Anesthesia Drugs Global Intravenous Injection General Anesthesia Drugs Revenue by Region: 2018-2029
3.3.1 Global Intravenous Injection General Anesthesia Drugs Revenue by Region: 2018-2023
3.3.2 Global Intravenous Injection General Anesthesia Drugs Revenue by Region: 2024-2029
3.4 North America Intravenous Injection General Anesthesia Drugs Market Facts & Figures by Country
3.4.1 North America Intravenous Injection General Anesthesia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Intravenous Injection General Anesthesia Drugs Sales by Country (2018-2029)
3.4.3 North America Intravenous Injection General Anesthesia Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Intravenous Injection General Anesthesia Drugs Market Facts & Figures by Country
3.5.1 Europe Intravenous Injection General Anesthesia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Intravenous Injection General Anesthesia Drugs Sales by Country (2018-2029)
3.5.3 Europe Intravenous Injection General Anesthesia Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Intravenous Injection General Anesthesia Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Intravenous Injection General Anesthesia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Intravenous Injection General Anesthesia Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Intravenous Injection General Anesthesia Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Intravenous Injection General Anesthesia Drugs Market Facts & Figures by Country
3.7.1 Latin America Intravenous Injection General Anesthesia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Intravenous Injection General Anesthesia Drugs Sales by Country (2018-2029)
3.7.3 Latin America Intravenous Injection General Anesthesia Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Intravenous Injection General Anesthesia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Intravenous Injection General Anesthesia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Intravenous Injection General Anesthesia Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Intravenous Injection General Anesthesia Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Intravenous Injection General Anesthesia Drugs Sales by Type (2018-2029)
4.1.1 Global Intravenous Injection General Anesthesia Drugs Sales by Type (2018-2023)
4.1.2 Global Intravenous Injection General Anesthesia Drugs Sales by Type (2024-2029)
4.1.3 Global Intravenous Injection General Anesthesia Drugs Sales Market Share by Type (2018-2029)
4.2 Global Intravenous Injection General Anesthesia Drugs Revenue by Type (2018-2029)
4.2.1 Global Intravenous Injection General Anesthesia Drugs Revenue by Type (2018-2023)
4.2.2 Global Intravenous Injection General Anesthesia Drugs Revenue by Type (2024-2029)
4.2.3 Global Intravenous Injection General Anesthesia Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Intravenous Injection General Anesthesia Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Intravenous Injection General Anesthesia Drugs Sales by Application (2018-2029)
5.1.1 Global Intravenous Injection General Anesthesia Drugs Sales by Application (2018-2023)
5.1.2 Global Intravenous Injection General Anesthesia Drugs Sales by Application (2024-2029)
5.1.3 Global Intravenous Injection General Anesthesia Drugs Sales Market Share by Application (2018-2029)
5.2 Global Intravenous Injection General Anesthesia Drugs Revenue by Application (2018-2029)
5.2.1 Global Intravenous Injection General Anesthesia Drugs Revenue by Application (2018-2023)
5.2.2 Global Intravenous Injection General Anesthesia Drugs Revenue by Application (2024-2029)
5.2.3 Global Intravenous Injection General Anesthesia Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Intravenous Injection General Anesthesia Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Aspen Pharma
6.1.1 Aspen Pharma Corporation Information
6.1.2 Aspen Pharma Description and Business Overview
6.1.3 Aspen Pharma Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Aspen Pharma Intravenous Injection General Anesthesia Drugs Product Portfolio
6.1.5 Aspen Pharma Recent Developments/Updates
6.2 Fresenius-Kabi
6.2.1 Fresenius-Kabi Corporation Information
6.2.2 Fresenius-Kabi Description and Business Overview
6.2.3 Fresenius-Kabi Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Fresenius-Kabi Intravenous Injection General Anesthesia Drugs Product Portfolio
6.2.5 Fresenius-Kabi Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AbbVie Intravenous Injection General Anesthesia Drugs Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Baxter Healthcare
6.4.1 Baxter Healthcare Corporation Information
6.4.2 Baxter Healthcare Description and Business Overview
6.4.3 Baxter Healthcare Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Baxter Healthcare Intravenous Injection General Anesthesia Drugs Product Portfolio
6.4.5 Baxter Healthcare Recent Developments/Updates
6.5 B.Braun
6.5.1 B.Braun Corporation Information
6.5.2 B.Braun Description and Business Overview
6.5.3 B.Braun Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 B.Braun Intravenous Injection General Anesthesia Drugs Product Portfolio
6.5.5 B.Braun Recent Developments/Updates
6.6 Maruishi
6.6.1 Maruishi Corporation Information
6.6.2 Maruishi Description and Business Overview
6.6.3 Maruishi Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Maruishi Intravenous Injection General Anesthesia Drugs Product Portfolio
6.6.5 Maruishi Recent Developments/Updates
6.7 Piramal
6.6.1 Piramal Corporation Information
6.6.2 Piramal Description and Business Overview
6.6.3 Piramal Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Piramal Intravenous Injection General Anesthesia Drugs Product Portfolio
6.7.5 Piramal Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Corporation Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikma Pharmaceuticals Intravenous Injection General Anesthesia Drugs Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AstraZeneca Intravenous Injection General Anesthesia Drugs Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Nhwa
6.10.1 Nhwa Corporation Information
6.10.2 Nhwa Description and Business Overview
6.10.3 Nhwa Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Nhwa Intravenous Injection General Anesthesia Drugs Product Portfolio
6.10.5 Nhwa Recent Developments/Updates
6.11 Hengrui
6.11.1 Hengrui Corporation Information
6.11.2 Hengrui Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.11.3 Hengrui Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Hengrui Intravenous Injection General Anesthesia Drugs Product Portfolio
6.11.5 Hengrui Recent Developments/Updates
6.12 Xi'an Libang
6.12.1 Xi'an Libang Corporation Information
6.12.2 Xi'an Libang Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.12.3 Xi'an Libang Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Xi'an Libang Intravenous Injection General Anesthesia Drugs Product Portfolio
6.12.5 Xi'an Libang Recent Developments/Updates
6.13 Yichang Humanwell
6.13.1 Yichang Humanwell Corporation Information
6.13.2 Yichang Humanwell Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.13.3 Yichang Humanwell Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Yichang Humanwell Intravenous Injection General Anesthesia Drugs Product Portfolio
6.13.5 Yichang Humanwell Recent Developments/Updates
6.14 China National Medicines Guorui Pharmaceutical Co.,Ltd.
6.14.1 China National Medicines Guorui Pharmaceutical Co.,Ltd. Corporation Information
6.14.2 China National Medicines Guorui Pharmaceutical Co.,Ltd. Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.14.3 China National Medicines Guorui Pharmaceutical Co.,Ltd. Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 China National Medicines Guorui Pharmaceutical Co.,Ltd. Intravenous Injection General Anesthesia Drugs Product Portfolio
6.14.5 China National Medicines Guorui Pharmaceutical Co.,Ltd. Recent Developments/Updates
6.15 Maruishi
6.15.1 Maruishi Corporation Information
6.15.2 Maruishi Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.15.3 Maruishi Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Maruishi Intravenous Injection General Anesthesia Drugs Product Portfolio
6.15.5 Maruishi Recent Developments/Updates
6.16 Lunan Pharmaceutical Group Corporation
6.16.1 Lunan Pharmaceutical Group Corporation Corporation Information
6.16.2 Lunan Pharmaceutical Group Corporation Intravenous Injection General Anesthesia Drugs Description and Business Overview
6.16.3 Lunan Pharmaceutical Group Corporation Intravenous Injection General Anesthesia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Lunan Pharmaceutical Group Corporation Intravenous Injection General Anesthesia Drugs Product Portfolio
6.16.5 Lunan Pharmaceutical Group Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Intravenous Injection General Anesthesia Drugs Industry Chain Analysis
7.2 Intravenous Injection General Anesthesia Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Intravenous Injection General Anesthesia Drugs Production Mode & Process
7.4 Intravenous Injection General Anesthesia Drugs Sales and Marketing
7.4.1 Intravenous Injection General Anesthesia Drugs Sales Channels
7.4.2 Intravenous Injection General Anesthesia Drugs Distributors
7.5 Intravenous Injection General Anesthesia Drugs Customers
8 Intravenous Injection General Anesthesia Drugs Market Dynamics
8.1 Intravenous Injection General Anesthesia Drugs Industry Trends
8.2 Intravenous Injection General Anesthesia Drugs Market Drivers
8.3 Intravenous Injection General Anesthesia Drugs Market Challenges
8.4 Intravenous Injection General Anesthesia Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
